CR8800A - Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona - Google Patents

Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona

Info

Publication number
CR8800A
CR8800A CR8800A CR8800A CR8800A CR 8800 A CR8800 A CR 8800A CR 8800 A CR8800 A CR 8800A CR 8800 A CR8800 A CR 8800A CR 8800 A CR8800 A CR 8800A
Authority
CR
Costa Rica
Prior art keywords
conceptive
concepts
systems
progesterone
receiver
Prior art date
Application number
CR8800A
Other languages
English (en)
Inventor
Sondermann Grubb Gary
Dale Constantine Ginger
Fensome Andrew
Cameron Mccomas Casey
George Melenski Edward
Anthony Marella Michael
Edward Wrobel Jay
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8800(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8800A publication Critical patent/CR8800A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un metodo para la anticoncepcion, que comprende suministrar de 21 a 27 dias consecutivos de uno o mas antagonistas de PR en la ausencia de una progestina, estrogeno, u otro compuesto esteroidal, seguido por de 1 a 7 dias sin ningun agente activo; tambien se describe un equipo farmaceuticamente util para facilitar el suministro de este regimen.
CR8800A 2004-07-07 2006-12-07 Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona CR8800A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58588304P 2004-07-07 2004-07-07
US67613505P 2005-04-29 2005-04-29

Publications (1)

Publication Number Publication Date
CR8800A true CR8800A (es) 2007-08-28

Family

ID=35106665

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8800A CR8800A (es) 2004-07-07 2006-12-07 Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona

Country Status (20)

Country Link
US (1) US20060009509A1 (es)
EP (1) EP1773323A1 (es)
JP (1) JP2008505906A (es)
KR (1) KR20070039912A (es)
AR (1) AR049664A1 (es)
AU (1) AU2005271974A1 (es)
BR (1) BRPI0512993A (es)
CA (1) CA2571198A1 (es)
CR (1) CR8800A (es)
EC (1) ECSP077131A (es)
GT (1) GT200500186A (es)
IL (1) IL180238A0 (es)
MX (1) MXPA06014580A (es)
NO (1) NO20070377L (es)
PA (1) PA8638501A1 (es)
PE (1) PE20060485A1 (es)
RU (1) RU2006144069A (es)
SV (1) SV2006002166A (es)
TW (1) TW200605880A (es)
WO (1) WO2006017075A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
TW200603813A (en) 2004-07-07 2006-02-01 Wyeth Corp Cyclic progestin regimens and kits
EP1768625B1 (en) 2004-07-09 2011-02-09 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
RU2011119626A (ru) 2008-10-17 2012-11-27 Ксенон Фармасьютикалз Инк. Спирооксиндольные соединения и их применение в качестве терапевтичеких средств
BRPI1014035A2 (pt) 2009-04-14 2016-04-12 Hra Pharma Lab método para contracepção.
PE20120432A1 (es) 2009-06-18 2012-05-05 Pfizer Compuestos biciclicos y triciclicos como inhibidores de kat ii
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
EP2488531B1 (en) 2009-10-14 2014-03-26 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
JP2013544277A (ja) 2010-12-01 2013-12-12 ファイザー・インク Ｋａｔｉｉ阻害剤
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP2016510791A (ja) * 2013-03-14 2016-04-11 ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ 排卵の予定を決める方法
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
CN107847506A (zh) 2015-06-22 2018-03-27 来普卡公司 含17‑羟基孕酮酯的口服组合物和相关方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
EP1773323A1 (en) 2007-04-18
RU2006144069A (ru) 2008-08-20
PA8638501A1 (es) 2006-07-03
MXPA06014580A (es) 2007-03-23
US20060009509A1 (en) 2006-01-12
IL180238A0 (en) 2007-07-04
WO2006017075A1 (en) 2006-02-16
AR049664A1 (es) 2006-08-23
NO20070377L (no) 2007-02-07
PE20060485A1 (es) 2006-06-24
CA2571198A1 (en) 2006-02-16
JP2008505906A (ja) 2008-02-28
GT200500186A (es) 2006-03-02
TW200605880A (en) 2006-02-16
KR20070039912A (ko) 2007-04-13
AU2005271974A1 (en) 2006-02-16
SV2006002166A (es) 2006-05-09
ECSP077131A (es) 2007-02-28
BRPI0512993A (pt) 2008-04-22

Similar Documents

Publication Publication Date Title
CR8800A (es) Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona
AR049707A1 (es) Regimenes y kits de progestina ciclica
AR074528A1 (es) Dispositivos intravaginales con un soporte rigido, metodos para su fabricacion y sus usos
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
ATE369125T1 (de) Bioadhäsiver schaumstoffilm mit hinhaltender wirkstoffreigabe
NZ615430A (en) Method for on-demand contraception
DK1768625T3 (da) Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer
PE20130524A1 (es) Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
NO20062945L (no) Forlenget anvendelseskombinasjon omfattende ostrogener og progestiner
PE20070208A1 (es) Anticoncepcion oral con trimegestona
ECSP055629A (es) COMPOSICIÓN QUE CONTIENE UN ESTEROIDE 11ß-HALOGENADO ANDRÓGENO Y UN GESTÁGENO ASÍ COMO UN CONTRACEPTIVO MASCULINO SOBRE LA BASE DE ESTAS COMPOSICIONES
PE20060314A1 (es) Prodrogas de estriol y estetrol
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
ATE500834T1 (de) Kontrazeptivum
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
AR070302A1 (es) Composicion farmaceutica de un sistema de liberacion vaginal de esteroides
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
PT1635843E (pt) Terapia de substituição hormonal e de depressão compreendendo dienogest
DOP2007000122A (es) Forma farmacologica peroral para anticoncepcion
AR036227A1 (es) USO DE LIGANDOS SELECTIVOS PARA ERa PARA REGULAR LA FERTILIDAD.
PE20010665A1 (es) Una composicion farmaceutica de drospirenona y etinilestradiol para ser usada como anticonceptivo
PE20091020A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa
DOP2005000263A (es) Emplasto transdermico con ligandos especificos de progesterona a (prasl) como principio activo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)